The Hormonal and Reproductive Epidemiology Branch (HREB) conducts research to identify groups at high risk of cancer, clarify the natural history of various cancers, understand the interactive effects of genetic and environmental factors on cancer risk, and elucidate biologic mechanisms of carcinogenesis.
HREB's research mission is to focus on hormonal and reproductive cancers, and other malignancies with possible hormonal etiologies (e.g., liver, esophageal). Learn about specific HREB research areas.
HREB fellows enjoy unique opportunities to collaborate and learn from investigators in a world-renowned research program. Fellows have access to large population-based studies with biological specimens and are encouraged to initiate new investigations and to compete for funding. Meet the current HREB fellows and learn about research training opportunities in HREB.
HREB launched the Distinguished Lecture Series in 2004. Each year, a prominent scientist is invited to visit for two days to give a lecture and meet with DCEG staff to discuss issues relevant to research on causes of hormonal and reproductive cancers. The objectives of this series are to expand and intensify contacts between intramural and extramural investigators, provide an opportunity for junior staff to meet with distinguished scientists, and stimulate new opportunities for research in the area of hormonal and reproductive cancers. Read more about the HREB Distinguished Lecture Series.
Dr. Nicolas Wentzensen is now a Senior Investigator in HREB. Read more on Dr. Nicolas Wentzensen.
Brinton LA*, Cook MB*, et al. Anthropometric and hormonal risk factors for male breast cancer: Male Breast Cancer Pooling Project results. J Natl Cancer Inst 2014;106:djt465. *Co-first authors.
Figueroa JD*, Ye Y*, Siddiq A*, Garcia-Closas M*, Chatterjee N*, Prokunina-Olsson L*, et al. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet 2014;23:1387-98. *Co-first authors.
Trabert B, Ness RB, et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst 2014;106:djt431.